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Abstract
Background: Among people living with HIV/AIDS, nutritional support is increasingly recognized as a critical part of
the essential package of care, especially for patients in sub-Saharan Africa. The objectives of the study were to
evaluate the outcomes of HIV-positive malnourished adults treated with ready-to-use therapeutic food and to
identify factors associated with nutrition programme failure.
Methods: We present results from a retrospective cohort analysis of patients aged 15 years or older with a body
mass index of less than 17 kg/m
2 enrolled in three HIV/AIDS care programmes in Africa between March 2006 and
August 2008. Factors associated with nutrition programme failure (patients discharged uncured after six or more
months of nutritional care, defaulting from nutritional care, remaining in nutritional care for six or more months, or
dead) were investigated using multiple logistic regression.
Results: Overall, 1340 of 8685 (15.4%) HIV-positive adults were enrolled in the nutrition programme. At admission,
median body mass index was 15.8 kg/m
2 (IQR 14.9-16.4) and 12% received combination antiretroviral therapy
(ART). After a median of four months of follow up (IQR 2.2-6.1), 524 of 1106 (47.4%) patients were considered
cured. An overall total of 531 of 1106 (48.0%) patients failed nutrition therapy, 132 (11.9%) of whom died and 250
(22.6%) defaulted from care. Men (OR = 1.5, 95% CI 1.2-2.0), patients with severe malnutrition at nutrition
programme enrolment (OR = 2.2, 95% CI 1.7-2.8), and those never started on ART (OR = 4.5, 95% CI 2.7-7.7 for
those eligible; OR = 1.6, 95% CI 1.0-2.5 for those ineligible for ART at enrolment) were at increased risk of nutrition
programme failure. Diagnosed tuberculosis at nutrition programme admission or during follow up, and presence of
diarrhoeal disease or extensive candidiasis at admission, were unrelated to nutrition programme failure.
Conclusions: Concomitant administration of ART and ready-to-use therapeutic food increases the chances of
nutritional recovery in these high-risk patients. While adequate nutrition is necessary to treat malnourished HIV
patients, development of improved strategies for the management of severely malnourished patients with HIV/
AIDS are urgently needed.
Background
Sub-Saharan Africa is the hardest hit area by the HIV
epidemic; it is home to 67% of the estimated 33 million
people living with HIV/AIDS worldwide [1]. The highest
HIV infection rates are found in southern and east
Africa, where adult HIV prevalence can exceed 25%, and
food shortages, along with malnutrition and HIV/AIDS,
have led some countries to the edge of crisis. Nutritional
support is often identified as one of the most immediate
and critical needs for people living with HIV/AIDS [2].
Weight loss is common in HIV/AIDS infection. HIV
progressively weakens the immune system and impairs
nutritional status through the reduction of intake, absorp-
tion and use of nutrients, and increased metabolism
needs [2,3]. Malnutrition can in turn exacerbate the effects
of HIV by increasing susceptibility to AIDS-related
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any medium, provided the original work is properly cited.illnesses [4,5]. Recommendations have been made to inte-
grate nutrition into the essential package of care, treat-
ment and support for people living with HIV/AIDS.
However, effective interventions to achieve this are still
lacking.
Several studies have provided evidence of the effective-
ness of ready-to-use therapeutic food (RUTF) for treat-
ment of acute malnutrition in HIV-infected and
uninfected children [6,7]. However, few data evaluating
the effect of RUTF in HIV-infected, malnourished adults
are available [8,9], and to our knowledge, no study has
investigated factors related to nutrition programme fail-
ure in this patient population.
In mid-2006, Médecins Sans Frontières/Doctors With-
out Borders (MSF), in collaboration with the ministries of
health of Uganda and Kenya, began providing RUTF to all
severely malnourished HIV patients followed in the HIV/
AIDS programmes of Arua in rural north-western Uganda,
Homa Bay in rural north-eastern Kenya, and Mathare
slum in Nairobi, Kenya. The RUTF provided is an energy-
dense spread of peanut, milk powder, oil and sugar, highly
fortified with micronutrients, originally designed for the
treatment of childhood severe acute malnutrition. The
objectives of this analysis were to evaluate the nutritional
outcomes of HIV-infected malnourished adults treated
with RUTF in these three MSF-supported HIV/AIDS
programmes in Africa from 2006 to 2008, and to identify
factors associated with nutrition treatment failure.
Methods
HIV care and treatment programme
The Arua Regional Referral Hospital in Uganda serves as
the tertiary health care facility for seven districts covering
a rural population of more than 2 million people. Homa
Bay District Hospital in Kenya is a referral hospital cover-
ing a rural area of around 300,000 inhabitants. In Arua
and Homa Bay, MSF, in collaboration with the respective
country’s Ministry of Health, provides outpatient and inpa-
tient HIV and tuberculosis (TB) care. The Mathare clinic
is a stand-alone clinic, located in Nairobi, providing HIV
and TB treatment and care for people living in the slum.
When necessary, patients are referred for hospitalization.
All diagnosed HIV-infected patients were eligible for
enrolment in the Arua and Mathare programmes, but
only patients diagnosed with World Health Organization
(WHO) stage 3 or 4 conditions were enrolled in Homa
Bay. Eligibility criteria for starting combination antire-
troviral therapy (ART) were those recommended in the
2006 WHO guidelines for scaling up ART in resource-
poor settings: all patients with WHO clinical stage 4, or
patients with CD4 counts of less than 200 cells/mm
3.
CD4 cell counts were monitored at ART start, at six
months, and yearly after the first year of therapy. No
routine viral load monitoring was performed.
When a new patient is eligible for ART, he/she
receives three pre-ART counselling sessions: first, on the
day of ART eligibility assessment; second, two weeks
later; and third, one to two weeks thereafter. The pro-
cess takes between 15 to 30 days, but may vary accord-
ing to patient clinical status or readiness to initiate ART.
Nutrition programme
Malnourished adults (aged 15 years or older in Kenyan
and 18 years or older in Ugandan programmes) enrolled in
the HIV/AIDS programmes received therapeutic feeding if
their body mass index (BMI) was less than 17 kg/m
2 or
they had bilateral pitting oedema at the lower extremities.
Patients received four sachets of RUTF (2000 kcal; Plum-
py’nut
®, Nutriset, Malaunay, France) per day in the outpa-
tient clinic, and were clinically assessed every two weeks or
monthly before renewal of the RUTF prescription.
The predefined nutrition programme (NP) exit criter-
ion was BMI ≥18 kg/m
2 with no oedema for at least
two consecutive weeks (defined as “cured” according to
the programme’s definition). After enrolment in the NP,
patients meeting the predefined NP exit criterion at any
time were discharged from the programme after full
clinical review. Patients unresponsive to nutritional ther-
apy after six months of treatment (not reaching BMI
≥18 kg/m
2; i.e., not meeting the predefined NP exit cri-
terion) were reviewed by a physician for further investi-
gations and management. After clinical assessment to
exclude presence of undiagnosed pathologies, they were
discharged from the NP. They were also referred to
patient support groups and given normal food support
(corn-soya blend, beans and oil) through aid agencies.
This latter group of patients was defined as discharged
“uncured” according to the programme’s definition.
Data collection
At each patient’s visit, anonymous individual HIV and
nutritional data were routinely collected on standardized
forms and entered into FUCHIA software database (Epi-
centre, Paris, France) and EpiData (version 3.1, EpiData
Association, Odense, Denmark). Data collected included
sex, age, enrolment dates in the HIV and nutrition pro-
grammes, follow-up visit dates, ART regimen prescribed
during the visit, weight, height, BMI at NP admission
and discharge, presence of oedema, opportunistic infec-
tions diagnosed at each visit, CD4 count, blood collec-
tion dates, and NP outcome categorized as cured,
discharged uncured, defaulted, treatment stopped, trans-
ferred to another HIV programme, or death.
Study design and population
We retrospectively analyzed the outcomes of all
HIV-positive adults followed in the three HIV/AIDS
care programmes who were eligible for nutritional
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nant women and HIV-positive patients enrolled in HIV
care before the availability of RUTF were excluded from
the analysis.
This multicentre study was based on analysis of routi-
nely collected, patient monitoring data from the three
programmes. In agreement with the Ministry of Health
of each country, clinical, therapeutic and laboratory
patient data are routinely collected for patient and pro-
gramme monitoring; as such, no formal ethics approval
from institutional review boards and/or written patient
consent were required. Local health authorities were
informed of the data analysis and potential publication
of findings, with written approval obtained from the
Kenyan health authorities and verbal approval from the
Ugandan health authorities. Databases were anonymized
before data compilation and analysis, and findings were
shared with our partners in the health ministries.
Definitions and data analysis
A patient was considered severely malnourished at
admission if BMI was less than 16 kg/m
2 and moder-
ately malnourished if BMI was 16-17 kg/m
2.N e w
patients were those admitted into the NP within one
month of enrolment in the HIV/AIDS care programme.
Patients were classified according to their ART status at
NP admission as: not eligible for ART; on ART; eligible
and started on ART at or after NP admission; and eligi-
ble but never started on ART. Defaulters from nutrition
care were patients who missed two or more consecutive
NP visits.
NP outcomes were defined as: programme success
(patients discharged from the NP and “cured” according
to the predefined NP exit criterion); programme failure
(patients discharged “uncured” according to the prede-
fined NP exit criterion, on NP care for six months or
more, defaulting from NP, or dead); or other (patients
who experienced intolerance to RUTF, stopped nutri-
tional therapy on request or for other reasons, or were
transferred to another HIV programme). The overall
programme failure rate was calculated by dividing the
total number of failure outcomes (discharged uncured,
died, defaulted, or still in the NP for six months or
more) by the total number of patients admitted into the
NP, excluding those who were receiving nutrition ther-
apy for more than 6 months and were still followed in
the NP. In sensitivity analyses, patients who stopped
nutrition therapy for intolerance or other reasons were
also considered NP failures.
We only considered the first recorded episode of mal-
nutrition for each patient. Data were described using
standard statistics for continuous and categorical vari-
ables, and compared with non-parametric, c
2, or Fisher’s
exact tests, as appropriate.
To investigate associations with NP failure, factors sig-
nificantly associated with the outcome in univariate ana-
lyses (p < 0.20) were included in a multiple logistic
regression model [10]. The final model was obtained
through the backward-stepwise procedure and the good-
ness-of-fit c
2 test was used to determine the fit of the
model [11]. Patients still on nutritional therapy and in
the NP for 6 months or less were excluded from this
analysis because they did not yet have an NP outcome.
To investigate whether the results were robust to
changes in our definition of failure, we performed two sen-
sitivity analyses using alternative programme failure defini-
tions. First, we excluded patients with NP outcome
defined as “other” (Model 1). Second, we classified patients
with intolerance to RUTF and those who stopped nutri-
tional therapy for other reasons as “programme failure”,
and those referred to another programme as “programme
success” (Model 2). All analyses were performed using
Stata 9.2 (Stata Corp., College Station, TX, USA).
Results
Patient characteristics at nutrition programme admission
Overall, 8685 HIV-positive adults were enrolled in the
three HIV care programmes between NP start (March
2006 for Kenyan and July 2006 for Ugandan pro-
grammes) and August 2008. A total of 1340 of 8685
(15.4%) HIV-positive adults were eligible for RUTF
treatment and enrolled in the NP. Of those admitted
and enrolled into the NP, 1057 (78.8%) patients had
been discharged at the time of the analysis, and the
remaining 283 (21.2%) were still receiving NP therapy,
234 of these for less than six months and 49 for six
months or more. The 234 patients who had received NP
therapy for less than six months and had not been dis-
charged were excluded from further analyses, and the
49 patients who were receiving NP for six months or
more were classified as “uncured”.
We describe the characteristics at NP admission for
the 1106 patients (Table 1). A total of 56.7% (627 of
1106) of patients were women, and median age was 33
years (IQR 28-40). Seventy-seven percent were enrolled
in the NP within one month of admission in the HIV/
AIDS care programme. Patients already followed in the
HIV programme for more than one month were in care
for a median of 2.3 months (IQR 1.5-4.7). At admission,
median BMI was 15.8 kg/m
2 (IQR 14.9-16.4), 617
(55.8%) patients had severe malnutrition (<16 kg/m
2),
and 489 (44.2%) had moderate malnutrition (16-17 kg/
m
2). Median CD4 count at NP admission was 114 cells/
mm
3 (IQR 37-268) (n = 806), and 65.9% (705 of 1070)
of patients were in HIV clinical stage 3 or 4. At enrol-
ment, the most frequently diagnosed opportunistic
infections were TB (n = 194), chronic diarrhoea (n =
113), and fever of unknown aetiology (n = 82).
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as eligible for ART according to the recorded clinico-
immunological information. Of those eligible for treat-
ment, 133 initiated ART before, and 470 at or after, NP
admission; 187 never received ART. Most patients on
ART prior to NP admission received a combination of
two nucleoside reverse transcriptase inhibitor (NRTI)
and one non-NRTI (NNRTI) drugs for a median of 0.5
months (IQR 0-2.6).
Median age and sex distribution were independent of
ART status (data not presented). However, median BMI
at admission was slightly lower in patients who were
e l i g i b l ef o rb u tn e v e rs t a r t e dA R T( 1 5 . 4k g / m
2;I Q R
14.2-16.3) than in the other groups: 15.9 kg/m
2 (IQR
Table 1 Characteristics of HIV-infected adults at admission, by outcome at discharge, in three nutritional therapy
programmes in Kenya and Uganda, 2006-2008
Characteristics Cured n = 524
(47.4%)
Not cured n = 149
(13.5%)
Defaulted n = 250
(22.6%)
Died n = 132
(11.9%)
Other
a n=5 1
(4.6%)
Total N =
1106
Demographic factors
Women (%) 323 (61.6) 79 (53.0) 128 (51.2) 64 (48.5) 33 (64.7) 627 (56.7)
c
Median age, years [IQR] 32 [27-40] 35 [29-40] 33 [27-40] 34 [30-42] 35 [27-44] 33 [28-40]
f
Follow up in HIV care
New patients (%) 398 (76.0) 116 (77.9) 208 (83.2) 102 (77.3) 32 (62.8) 856 (77.4)
d
In HIV care (%) 126 (24.0) 33 (22.1) 42 (16.8) 30 (22.7) 19 (37.2) 250 (22.6)
Nutritional status
a
BMI, kg/m
2, median [IQR] 16.0 [15.4-16.5] 15.5 [14.6-16.3] 15.6 [14.3-16.3] 15.2 [14.0-16.2] 15.5 [14.3-16.4] 15.8 [14.9-16.4]
e
Severe malnutrition, BMI
<16 kg/m
2 (%)
245 (46.8) 96 (64.4) 157 (62.8) 91 (68.9) 28 (54.9) 617 (55.8)
e
Moderate malnutrition, BMI
16-17 kg/m
2 (%)
279 (53.2) 53 (35.6) 93 (37.2) 41 (31.1) 23 (45.1) 489 (44.2)
Clinical & immunological
factors
Non-cumulative HIV
clinical stage (%)
n = 508 n = 143 n = 242 n = 128 n = 49 n = 1070
c
Asymptomatic 40 (7.9) 10 (7.0) 20 (8.3) 12 (9.4) 5 (10.2) 87 (8.1)
1 or 2 149 (29.3) 48 (33.5) 50 (20.7) 21 (16.4) 10 (20.4) 278 (26.0)
3 248 (48.8) 65 (45.5) 119 (49.2) 65 (50.8) 23 (46.9) 520 (48.6)
4 71 (14.0) 20 (14.0) 53 (21.8) 30 (23.4) 11 (22.5) 185 (17.3)
CD4 cell counts,
cells/mm
3
n = 411 n = 119 n = 155 n = 83 n = 38 n = 806
e
Median [IQR] 122 [46-272] 188 [86-360] 94 [24-232] 39 [17-126] 74 [42-206] 114 [37-268]
<50 (%) 111 (27.0) 25 (21.0) 61 (39.3) 46 (55.5) 14 (36.8) 257 (31.9)
50-200 (%) 161 (39.2) 36 (30.3) 46 (29.7) 24 (28.9) 14 (36.8) 281 (34.9)
>200 (%) 139 (33.8) 58 (48.7) 48 (31.0) 13 (15.7) 10 (26.4) 268 (33.2)
ART status (%)
Not eligible for ART 132 (25.2) 56 (37.6) 89 (35.6) 29 (22.0) 10 (19.6) 316 (28.6)
e
On ART 68 (13.0) 17 (11.4) 23 (9.2) 20 (15.2) 5 (9.8) 133 (12.0)
ART started at/after
admission
298 (56.8) 70 (47.0) 46 (18.4) 36 (27.3) 20 (39.2) 470 (42.5)
Eligible but no ART 26 (5.0) 6 (4.0) 92 (36.8) 47 (35.5) 16 (31.4) 187 (16.9)
ART regimen (%)
b n = 68 n = 17 N = 23 n = 20 n = 5 n = 133
f
2 NRTI + 1 NNRTI 64 (94.1) 17 (100) 22 (95.7) 20 (100) 5 (100) 128 (96.2)
Second-line therapy 1 (1.5) 0 (0.0) 1 (4.3) 0 (0.0) 0 (0.0) 2 (1.5)
ART interrupted 3 (4.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.3)
aNo patients had recorded presence of bilateral oedema
bAmong the 133 patients already receiving ART at NP admission
cP < 0.01
dP = 0.02
eP < 0.0001
fP ≥ 0.05
ART - antiretroviral therapy; BMI - body mass index; IQR - interquartile range; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse
transcriptase inhibitor
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15.8 kg/m
2 (IQR 14.8-16.3) for those who initiated ART
at or after NP admission; and 16.0 kg/m
2 (IQR 15.2-
16.6) for those ineligible for ART (P = 0.002).
Nutritional outcomes
Of the 1106 patients admitted into the NP and dis-
charged, 524 (47.4%) were considered cured according
to the predefined NP exit criterion (programme suc-
cess), 149 (13.5%) discharged uncured, 250 (22.6%)
defaulted from NP care, 132 (11.9%) died, 26 (2.4%)
transferred to another programme, and 25 (2.3%)
stopped RUTF due to treatment intolerance or other
reasons (Table 2). The overall programme failure rate
was 48.0% (531 of 1106); if patients who transferred to
another programme or who stopped NP were also con-
sidered, programme failure rate was 52.6% (582 of
1106).
Cured patients were discharged from the NP after a
median of 3.7 months (IQR 2.2-6.1) of treatment (Table
2). At discharge, their daily weight gain since NP admis-
sion was 1.6 g/kg/day (IQR 1.0-2.6), median weight gain
achieved since NP admission was 8 kg (IQR 5.5-11.0),
and 57.1% (280/490) were in HIV clinical stage 1 or 2.
Patients uncured after nutritional therapy had been trea-
ted for a median of 7.1 months (IQR 5.9-9.6). A total of
67.4% (60 of 89) of these patients were in HIV clinical
stage 1 or 2, with median CD4 count of 292 cells/mm
3
(IQR 201-454), and no CD4 cell gain was observed dur-
ing NP follow up.
Median BMI at discharge was 16.7 kg/m
2 (IQR 15.8-
17.3) and daily weight gain since NP admission was 0.3
g/kg/day (IQR 0.1-0.6). Patients who defaulted from NP
care or died had received nutritional therapy for less
than three months and were severely malnourished
(median BMI at last visit 15.2 kg/m
2 [IQR 14.0-16.2]
and 14.9 kg/m
2 [IQR 13.4-16.0], respectively). Further-
more, 67.6% (96 of 142) of defaulting patients and 71.4%
(15 of 21) of deaths were in HIV clinical stage 3 or 4,
and were severely immunosuppressed at last visit (med-
ian CD4 counts 96 cells/mm
3 [IQR 33-214] and 36
cells/mm
3 [IQR 16-129], respectively).
When comparing ART eligibility among the patients
discharged, those eligible for but never started on ART
had the lowest median BMI (15.4 kg/m
2; IQR 14.0-16-6)
at discharge with no overall weight gain or daily weight
gain compared with other groups. These patients had
the highest death and default rates and lowest cure rates
Table 2 Characteristics of HIV-infected adults at discharge from three nutritional therapy programmes in Kenya and
Uganda, by nutrition outcome, 2006-2008
Patient characteristics Cured Not cured Defaulted Died Other
a Total
n = 524
(47.4%)
n = 149
(13.5%)
n = 250
(22.6%)
n = 132
(11.9%)
n = 51 (4.6%) N = 1106
Demographic factors
Women (%) 323 (61.6) 79 (53.0) 128 (51.2) 64 (48.5) 33 (64.7) 627 (56.7)
b
Age, years, median [IQR] 32 [27-40] 35 [29-42] 33 [27-40] 34 [30-42] 35 [27-44] 33 [28-40]
c
NP follow-up time, months, median [IQR] 3.7 [2.2-6.1] 7.1 [5.9-9.6] 2.3 [1.0-3.9] 1.6 [0.8-2.8] 2.8 [0.9-5.6] 3.3 [1.7-6.2]
c
Nutritional indicators
Daily weight gain, g/kg/d, median [IQR] 1.6 [1.0-2.6] 0.3 [0.1-0.6] 0 [-0.4-0.3] 0 [-1.1-0] 0.05 [-0.5-1] 0.8 [0-1.8]
c
Weight gain, kg median [IQR] 8 [5.5-11] 3 [1-5] 0 [-2-1] 0 [-3-0] 1 [-2.5-4] 4 [0-8]
c
BMI, kg/m
2 n = 524 n = 102 n = 230 n = 126 n = 47 n = 1029
Median [IQR] 18.7 [18.2-19.5] 16.7 [15.8-17.3] 15.2 [14.0-16.2] 14.9 [13.4-16.0] 15.8 [14.5-17.2] 17.7 [15.6-18.8]
c
Clinical & immunological factors
Non-cumulative HIV clinical stage (%) n = 490 n = 89 n = 142 n = 21 n = 42 n = 784
c
Asymptomatic 47 (9.6) 7 (7.9) 13 (9.2) 1 (4.8) 6 (14.3) 74 (9.4)
1 or 2 280 (57.1) 60 (67.4) 33 (23.2) 5 (23.8) 13 (31.0) 391 (49.9)
3 129 (26.4) 21 (23.6) 68 (47.9) 8 (38.1) 15 (35.7) 241 (30.7)
4 34 (6.9) 1 (1.1) 28 (19.7) 7 (33.3) 8 (19.0) 78 (10.0)
CD4 cell count, cells/mm
3 n = 173 n = 47 n = 63 n = 44 n = 18 n = 345
Median [IQR] 218 [106-363] 292 [201-454] 96 [33-214] 36 [16-129] 91.5 [45-431] 188 [58-349]
c
<200 (%) 78 (45.1) 11 (23.4) 44 (69.8) 36 (81.8) 10 (55.6) 179 (51.8)
c
aOther group includes patients who stopped RUTF for intolerance or other reason and those referred to another programme
bP < 0.01
cP < 0.0001
BMI - body mass index; IQR - interquartile range; NP - nutrition programme
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am e d i a nl e n g t ho fs t a yi nt h eN Po f1 . 9m o n t h s( I Q R
0.8-2.9), median CD4 count at last visit was 70 cells/
mm
3 (IQR 24-200), and 77% were in clinical stage 3 or
4. In contrast, patients who were eligible for and
initiated ART during NP care had the highest cure rate
(63.4%), weight gain (6.5 kg; IQR 3.0-10.0), and BMI
(18.3 kg/m
2; IQR 16.8-19.1) at discharge.
Factors associated with nutrition programme failure
Risk factor analysis was based on available information
from 507 adults successfully treated and 509 patients
who failed nutritional therapy. We excluded 234 patients
who received nutritional therapy for less than six
months.
Men (adjusted OR [ORa] 1.5, 95% CI 1.2-2.0) and
patients severely malnourished at NP admission (ORa
2.2, 95% CI 1.7-2.8) were at increased risk of NP failure
(Table 3). Furthermore, compared with patients who
were already receiving ART at NP admission, patients
who never initiated therapy despite being eligible (ORa
4.5, 95% CI 2.7-7.7) and patients not eligible for ART at
NP admission (ORa 1.6, 95% CI 1.0-2.5) were both at
increased risk of NP failure. Patients eligible for and
started on ART at or after NP admission were less likely
to fail nutritional therapy (ORa 0.6, 95% CI 0.4-0.9).
Diagnosed TB at NP admission or during follow up,
and presence of diarrhoeal disease or extensive candidia-
sis at admission, were unrelated to the risk of NP fail-
ure. P value from the goodness-of-fit test for the final
regression model was 0.11. The observed results were
robust to the sensitivity analyses using the alternative
definitions of NP failure and success (data not shown).
Discussion
In this evaluation of nutritional outcomes of HIV-
infected malnourished adults treated with RUTF in
three sub-Saharan African HIV/AIDS programmes, 15%
of all patients enrolled for HIV care were diagnosed
with acute malnutrition and received therapeutic nutri-
tional rehabilitation.
One in two patients was severely malnourished at NP
admission, and approximately three in four were
admitted into the NP within one month of HIV pro-
gramme enrolment. At NP admission, 64% of patients
had advanced HIV clinical disease and were severely
immunosuppressed (<200 cells/mm
3). Furthermore,
severely malnourished patients had a two-fold increased
risk of NP failure compared with moderately malnour-
ished patients, stressing the importance of closely moni-
toring the nutritional status of HIV patients, treating
malnutrition at early stages, and increasing early access
to HIV/AIDS care.
An important finding of this evaluation was that 70%
of patients were eligible for ART at NP admission, but
one in five were never initiated on therapy, probably
due to several reasons, such as delay of ART initiation
for TB co-infected patients after completion of the TB
intensive-phase treatment, delayed blood test results or
patient refusal. As expected, many of the patients who
needed but never received ART died (26%) or defaulted
( 5 0 % )f r o mc a r es h o r t l ya f t e rN Pe n r o l m e n ta n dh a da
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Figure 1 Outcomes of HIV-infected patients treated in three nutritional therapy programmes in Kenya and Uganda, by antiretroviral
therapy status*, 2006-2008. *N = 1106; proportion of patients by nutritional therapy outcome is presented for each category of ART status at
admission in the nutrition programme. ART - antiretroviral therapy
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including death, compared with patients already on
ART. These findings highlight the importance of inte-
grating HIV and nutrition care to carefully monitor
patient eligibility for ART and initiate therapy early to
prevent deaths.
This study also showed that that the risk of NP failure
was 1.6 times higher in patients not eligible for ART at
NP enrolment than in those already on ART at admis-
sion. This finding could reflect the existence of undiag-
nosed severe clinical conditions and/or severe HIV
disease, and suggests that ART should be provided to all
malnourished HIV-infected patients regardless of their
theoretical eligibility status to ART.
Furthermore, we observed that patients who initiated
ART while receiving nutrition treatment had lower risk
of NP failure than those already on ART. This is sup-
ported by evidence from a prospective study assessing
acceptability and effectiveness of a locally produced
RUTF in HIV-infected, chronically ill adults in Malawi
[8], where patients commencing ART prior to or while
on nutritional therapy experienced greater weight and
BMI gains. Furthermore, the greater frequency of visits
and support of counsellors at the time of ART start
Table 3 Factors associated with nutrition programme failure among HIV-infected adults treated in Kenya and Uganda,
2006-2008
Factors Adjusted (Model 1) Adjusted (Model 2)
OR (95% CI) P value OR (95% CI) P value
Treatment cohort
Arua 1.0 0.01 1.0 0.007
Homa Bay 1.5 (1.0-2.3) 1.7 (1.1-2.4)
Mathare 0.7 (0.4-1.0) 0.8 (0.5-1.1)
Period of admission in the NP
Years 2005 - 2006 1.0 0.1 1.0 0.1
January-June 2007 0.8 (0.5-1.2) 0.8 (0.6-1.2)
July 2007-June 2008 1.1 (0.8-1.6) 1.1 (0.8-1.2)
In the HIV programme
Patients already in care 1.0 0.5 1.0 0.5
New patients 1.1 (0.8-1.6) 1.1 (0.8-1.6)
Age at NP admission, years
≥45 1.0 0.2 1.0 0.4
30-44 1.0 (0.6-1.5) 1.0 (0.6-1.4)
15-29 0.7 (0.4-1.2) 0.8 (0.5-1.2)
Gender
Women 1.0 0.001 1.0 0.001
Men 1.6 (1.2-2.1) 1.5 (1.2-2.0)
Malnutrition at admission
Moderate 1.0 <0.0001 1.0 <0.0001
Severe 2.2 (1.7-3.0) 2.2 (1.7-2.8)
Recorded clinical diagnoses
TB at NP admission 0.9 (0.6-1.3) 0.7 0.9 (0.6-1.3) 0.6
TB diagnosed during NP follow up 1.0 (0.7-1.4) 0.9 1.0 (0.7-1.4) 0.9
Extensive candidiasis at NP admission 1.4 (0.6-3.4) 0.4 1.2 (0.5-2.6) 0.7
Diarrhoea at NP admission 1.3 (0.8-2.0) 0.3 1.3 (0.8-2.0) 0.3
ART status at admission
On ART 1.0 <0.0001 1.0 <0.0001
Eligible but never started on ART 6.2 (3.5-11.1) 4.5 (2.7-7.7)
Eligible & ART initiated at or after NP admission 0.5 (0.3-0.8) 0.6 (0.4-0.9)
Ineligible for ART 1.4 (0.9-2.3) 1.6 (1.0-2.5)
Model 1: Results from analysis where deaths, lost to follow up and uncured were classified as NP failure; and patients with NP outcome defined as “other” were
excluded from the model.
Model 2: Results from analysis where deaths, lost to follow up, uncured, patients with intolerance to RUTF and those who stopped nutritional therapy for other
reasons were classified as “programme failure”.
ART - antiretroviral therapy; NP - nutrition programme; OR - odds ratio; TB - tuberculosis
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also to nutritional therapy [12]. This could therefore
partly explain the better nutritional outcomes observed
in the group of patients who started ART while receiv-
ing nutrition support.
Overall, 50% of patients were cured after receiving
nutritional treatment for a median of four months and
achieved an average weight gain of 1.6 g/kg/day. HIV-
positive adults have higher energy requirements than
healthy non-HIV-infected individuals [2,13,14] due to
increased resting energy expenditure, presence of fever
and infection, diarrhoea and vomiting, and the need for
growth and weight recovery.
The RUTF in this study was originally developed to
treat severe acute malnutrition in HIV-uninfected chil-
dren [15,16]. Studies in Malawi have reported cure rates
of 86% and 75% for HIV-negative and HIV-positive chil-
dren receiving the same RUTF, respectively [6,17]. Since
only a paediatric formulation of this RUTF is currently
available, it is also used to treat malnourished HIV-posi-
tive adults, but it might not be the best nutritional option
for this patient population. Previous studies in HIV-posi-
tive adults showed that the quantity of RUTF intake is
positively associated with weight and BMI recovery [8];
therefore, poor adherence in some of the patients could
partly explain the low cure rates observed.
A recent qualitative study of RUTF acceptability
among HIV-positive adults in Homa Bay, Kenya, showed
that only half of the patients receiving the product actu-
ally complied with the full prescribed dose (2000 kcal/
day), due to poor taste, diet boredom, bulky weight (~12
kg; two-week supply needed to be carried by the patient,
and patients would tend to reduce their daily intakes to
ensure that the amount received lasted until the next
scheduled clinic visit), and sharing of supply with other
household members [18]. Further research is needed to
design and evaluate a RUTF better adapted to the speci-
fic needs of HIV-positive adults that might help improve
their nutritional status.
The highest cure rate was observed for patients receiv-
i n gR U T Fa n dw h ow e r ee l i g i ble for and initiated ART
at or after NP admission. In Malawi, a randomized con-
trolled trial compared outcomes of food supplementa-
tion in HIV-infected adults initiating ART and receiving
either RUTF (260 g/day, 1360 kcal/day) or corn-soya
blend (374 g/day, 1360 kcal/day) [9]. Patients in the
RUTF group achieved mean overall weight gain of 5.6
kg, with median BMI of 19.0 kg/m
2 after 3.5 months of
treatment. However, the proportion of patients with
moderate malnutrition was higher (67%), and all patients
were treated with ART, in contrast to our study
patients. In addition, no significant difference in mortal-
ity was observed between the two groups. Further stu-
dies are needed to evaluate the true impact on mortality
of nutritional rehabilitation among patients initiating
ART [19].
More than one in three patients died or defaulted
from care during the first three months of treatment,
and it is likely that many of the defaulting patients died
shortly after treatment initiation. Similarly, a previous
study reported an overall 27% death-defaulter rate in
Malawi [8], confirming that severe weight loss is asso-
ciated with both occurrence of severe opportunistic
infections and death [4,20-23].
In our study, men had an odds of failure 1.5 times
higher than women. Knowing that in our programmes,
men tend to access HIV care at a more clinically and/or
immunologically advanced stage of disease than women
[24], a higher risk of nutritional failure or death there-
fore exists in men. Gender differences in patient compli-
ance to nutritional treatment and/or ART could also
explain our findings.
The higher risk of NP failure observed in patients trea-
ted in the Homa Bay programme could be explained by
their more advanced stage of HIV disease at enrolment.
Indeed, at the time of the study, only advanced WHO
stage 3 and 4 patients were enrolled in the Homa Bay HIV
cohort and entered into the database. For patients with
less advanced HIV infection, clinical information was not
monitored with a computerized system. Therefore, these
patients have not been included in this analysis.
This retrospective cohort study was based on the ana-
lysis of routinely collected data from three HIV care
programmes. Indeed, certain types of information, such
as CD4 cell counts at NP admission, were missing for
some of the patients. Nevertheless, efforts were made in
the programmes to ensure and maintain the quality and
completeness of the data collected. Checks at data entry
and regular verifications of inconsistencies were routi-
nely performed.
Data from three different programmes were analyzed.
However, all used the same criteria for inclusion to and
discharge from the NP, applied the same criteria for
ART initiation, and provided the same antiretroviral
regimens. Information on household food availability,
dietary intake from other sources, or patient compliance
to nutrition therapy and/or ART was not available and
could have biased the results of our risk-factor analysis.
In addition, the absence of a comparison group did not
allow investigating the additional benefit of providing
RUTF to patients also receiving ART.
Conclusions
We have reported here on our first experience in treating
severely malnourished HIV-infected adults with RUTF in
three routine, home-based therapeutic feeding pro-
grammes in sub-Saharan Africa. In these programmes,
15% of the HIV patients in care required nutritional
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Page 8 of 9rehabilitation, and cure rates varied widely from 14% to
67%, according to the patient ART status at NP admission.
Despite the limitations of this observational study, our
findings suggest that the administration of nutrition
therapy, in conjunction with an early start of ART,
might increase the chances of nutritional recovery in
severely malnourished HIV patients. Furthermore, this
study shows that nutritional support with RUTF may be
more effective when provided to patients at earlier
stages of malnutrition. While adequate nutrition is
necessary to treat malnourished HIV patients and maxi-
mize the benefit of ART, there is still a need to clearly
define and evaluate the most effective ways of adminis-
tering such care.
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